N560-ADC

N560-ADC is a preclinical nanobody-drug conjugate (ADC) developed by Nanolattix for the treatment of solid tumors, including lung cancer, cervical cancer, and ovarian cancer. Unlike traditional ADCs that utilize monoclonal antibodies, N560-ADC employs a nanobody as its targeting moiety. Nanobodies, which are derived from camelid heavy-chain antibodies, are significantly smaller than conventional antibodies, potentially offering advantages such as improved tumor tissue penetration and higher stability. The specific molecular target of the nanobody and the nature of the cytotoxic payload have not been publicly disclosed by the developer.

Other names

N560 nanobody ADCN-560 nanobody ADCN 560 nanobody ADC